- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03660748
Safety and Efficacy of MET-3 in Obese Human Subjects
August 10, 2020 updated by: NuBiyota
A Phase I, Open-Label, Single-Centre Study of the Safety and Efficacy of Microbial Ecosystem Therapeutics (MET)-3 in Obese Human Subjects
A pilot study to explore the metabolic effect and safety of a 3-week course of therapy with MET-3 in obese subjects
Study Overview
Detailed Description
This is an open label, single center, uncontrolled pilot study of 20 participants; each group will receive a different dose of MET-3.
Each group will have 4-6 females, 4-6 participants with BMI 30.0-34.9 kg/m² and the remainder with BMI 35-39.9
kg/m.
Study Type
Interventional
Enrollment (Actual)
15
Phase
- Early Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5C2N8
- GI Labs
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or non-pregnant, non-lactating females who are taking adequate contraceptive precaution, aged 18 to 75 years inclusive;
- BMI ≥30.0 kg/m2 and <40.0 kg/m2;
- Stable body weight (±4 kg) for the past 4 months with no intention to gain or lose weight;
- Fasting serum triglycerides <6 mmol/L (<532 mg/dL) at screening;
- Fasting serum glucose <7.0 mmol/L (<126 mg/dl) and A1c<6.5% at screening
- Blood pressure <160/100.
- AST, ALT and ALP ≤1.8 times the upper limit of normal (liver function) at screening;
- Serum creatinine < 1.5 times the upper limit of normal (kidney function) at screening;
At least one of the following:
- Fasting serum glucose >5.6 mmol/L
- HbA1c > 6.0%
- Fasting triglycerides >1.70 mmol/L (150 mg/dl)
- AST > upper limit of normal
- Blood pressure, systolic >140 mmHg and/or diastolic >90 mmHg
- Willing to maintain habitual diet, physical activity pattern, and body weight throughout the trial;
- Willing to abstain from strenuous exercise, consuming alcoholic drinks 24 hours before study days and during study days;
- Willing to maintain current dietary supplement and medication use throughout the trial. On test days, subject agrees to bring any dietary supplements or medications taken in the morning with them to GI labs to take just prior to the glucose test meal;
- Subject is not currently participating nor recently (within 30 days of screening) participated in a clinical trial involving long-term exposure (greater than 24 hours) to an investigational drug, nutritional supplement or lifestyle modification;
- Understanding the study procedures and willing to provide informed consent to participate in the study and authorization to release relevant protected health information to the study investigator and other authorized agents as indicated in the consent form
Exclusion Criteria:
- Failure to meet any one of the inclusion criteria.
- Smokers
- Hemoglobin measurements of <120g/L for females and <130g/L for males (as per World Health Organization [WHO] criteria for anemia)
- Known history of acquired immune deficiency syndrome (AIDS), hepatitis, a history or presence of clinically important endocrine conditions (including Type 1 or Type 2 diabetes mellitus), pulmonary, biliary or gastrointestinal (GI) disorders or new onset cardiovascular disease within 6 months of screening (including, but not limited to, atherosclerotic disease, history of myocardial infarction, peripheral arterial disease, stroke).
- Use of medications known to influence carbohydrate metabolism, gastrointestinal function or appetite, including, but not limited to adrenergic blockers, diuretics, thiazolidinediones, metformin and systemic corticosteroids within 4 weeks of the screening visit, or with any condition which might, in the opinion of the Investigator, either: 1) make participation dangerous to the subject or to others, 2) affect the results, or 3) influence the ability of the subject to comply with study procedures.
- Major trauma or surgical event within 3 months of screening.
- Unwillingness or inability to comply with the experimental procedures and to follow GI Labs safety guidelines.
- Known intolerance, sensitivity or allergy to any ingredients in the investigational agent.
- Extreme dietary habits, as judged by the Investigator (i.e. Atkins diet, very high protein diets, etc.).
- Uncontrolled hypertension (systolic blood pressure ≥160 mm Hg or diastolic blood pressure ≥100 mm Hg as defined by the average blood pressure measured at screening.
- Presence of any signs or symptoms of an active infection within 5 d prior to any test visit. If an infection occurs during the study period, test visits should be rescheduled until all signs and symptoms have resolved and any treatment (i.e. antibiotic therapy) has been completed at least 5 d prior to each test visit.
- History of cancer in the prior two years, except for non-melanoma skin cancer.
- Recent history (within 12 months of screening) or strong potential for alcohol or substance abuse. Alcohol abuse is defined as > 14 drinks per week (1 drink=12 oz beer, 5 oz wine, or 1.5 oz distilled spirits).
- Pregnancy or breastfeeding
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Lower BMI
Use of MET-2 in subjects with BMI of 30.0 to 34.9
|
Ingestion of a novel human microbiome preparation
|
EXPERIMENTAL: Higher BMI
Use of MET-2 in subjects with BMI of 35 to 39.9
|
Ingestion of a novel human microbiome preparation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Effect of MET-3 on the Incremental Area under the glucose curve (2 hrs) in obese subjects
Time Frame: Treatment week 6
|
The area under the glucose curve in obese subjects will be measured 2 hours after a 75 g oral glucose challenge.
This measurement will be made at baseline and then again after 6 weeks of treatment with MET-3.
|
Treatment week 6
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Treatment-Emergent Adverse Events
Time Frame: Period beginning at enrollment and continuing through to end of treatment phase (week 6)
|
Adverse Events,Complete blood count (CBC), aspartate transaminase (AST), alanine aminotransferase (ALT), Alkaline phosphatase (ALP), bilirubin, urea, amylase, creatinine and electrolytes
|
Period beginning at enrollment and continuing through to end of treatment phase (week 6)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Thomas MS Wolever, MD/PhD, GI Labs
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
October 1, 2018
Primary Completion (ACTUAL)
January 22, 2020
Study Completion (ACTUAL)
January 22, 2020
Study Registration Dates
First Submitted
August 28, 2018
First Submitted That Met QC Criteria
September 4, 2018
First Posted (ACTUAL)
September 7, 2018
Study Record Updates
Last Update Posted (ACTUAL)
August 11, 2020
Last Update Submitted That Met QC Criteria
August 10, 2020
Last Verified
September 1, 2018
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- MET-3 101
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Central Hospital, Nancy, FranceNot yet recruiting
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingAdolescent ObesityUnited States
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
The Hospital for Sick ChildrenCompleted
-
Ihuoma EneliCompletedObesity, ChildhoodUnited States
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
-
Fundació Sant Joan de DéuNot yet recruitingObesity, Childhood | Obesity, AdolescentSpain
Clinical Trials on MET-2
-
NuBiyotaCompleted
-
NuBiyotaRecruitingAnxiety | Major Depressive DisorderCanada
-
NuBiyotaCompleted
-
Elcelyx Therapeutics, Inc.CompletedHealthy Subjects
-
University Health Network, TorontoNot yet recruitingMicrobial Colonization | Antibiotic Resistant Infection | Gram-negative BacteremiaCanada
-
NuBiyotaUnknownObesity, Metabolically BenignCanada
-
Dow University of Health SciencesCompletedMechanical Neck PainPakistan
-
University of ConnecticutNational Institute on Alcohol Abuse and Alcoholism (NIAAA)CompletedAlcohol ConsumptionUnited States
-
National Jewish HealthNational Heart, Lung, and Blood Institute (NHLBI); The Miriam Hospital; National...CompletedSleep Apnea, Obstructive | Continuous Positive Airway PressureUnited States
-
Elcelyx Therapeutics, Inc.CompletedType 2 Diabetes MellitusUnited States, Puerto Rico